evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Salbutamol vs placebo/no treatment

Need for continuous positive airway pressure (yes/no) · patients with the management of transient tachypnea of the newborn

It is very uncertain whether salbutamol changes need for continuous positive airway pressure (yes/no) compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Salbutamol vs placebo/no treatment

Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn

It is very uncertain whether salbutamol changes need for mechanical ventilation (yes/no) compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Carisbamate vs placebo

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).

1 finding from 1 review

Carisbamate vs placebo

Participants who experienced any adverse event Adverse event regardless of severity · people with drug‐resistant focal epilepsy

Carisbamate showed no clear difference in proportion of participants who experienced atleast 1 adverse event compared with placebo (low certainty).

1 finding from 1 review

Carisbamate vs placebo

Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy

Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).

1 finding from 1 review